Windlas Biotech Limited — Investor Meet, 11-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Windlas Biotech reported strong Q2 FY26 revenue up 19% to INR222 Cr and H1 FY26 revenue at INR432 Cr (+19% YoY). H1 EBITDA was INR55 Cr, PAT INR35 Cr, with gross margin expanding 70 bps. EPS for H1 FY26 grew 21% to INR16.91. Growth was balanced across CDMO, Trade Generics, and Exports. Plant-6 expansion for oral solids is on track; injectables are ramping up but slightly behind plan. Management focuses on efficiency and talent retention via ESOPs (total >INR50 Cr). Outlook positive leveraging quality and capability expansion.